Lonza Group Ltd (LZAGY)
54.20
+0.40
(+0.74%)
USD |
OTCM |
May 31, 16:00
Lonza Group Revenue (Annual): 7.480B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.480B |
| December 31, 2022 | 6.525B |
| December 31, 2021 | 5.918B |
| December 31, 2020 | 4.808B |
| December 31, 2019 | 4.235B |
| December 31, 2018 | 5.665B |
| December 31, 2017 | 4.617B |
| December 31, 2016 | 4.195B |
| December 31, 2015 | 3.952B |
| December 31, 2014 | 3.983B |
| Date | Value |
|---|---|
| December 31, 2013 | 3.868B |
| December 31, 2012 | 4.186B |
| December 31, 2011 | 3.047B |
| December 31, 2010 | 2.560B |
| December 31, 2009 | 2.485B |
| December 31, 2008 | 2.719B |
| December 31, 2007 | 2.393B |
| December 31, 2006 | 1.825B |
| December 31, 2005 | 2.026B |
| December 31, 2004 | 1.759B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
4.235B
Minimum
2019
7.480B
Maximum
2023
5.793B
Average
5.918B
Median
2021
Revenue (Annual) Benchmarks
| Roche Holding AG | 67.31B |
| AC Immune SA | 16.48M |
| CRISPR Therapeutics AG | 370.00M |
| Addex Therapeutics Ltd | 1.796M |
| NLS Pharmaceutics Ltd | -- |